These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26270682)

  • 1. Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.
    Trooskin SB; Reynolds H; Kostman JR
    Clin Infect Dis; 2015 Dec; 61(12):1825-30. PubMed ID: 26270682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment.
    Tumber MB
    J Leg Med; 2017; 37(1-2):21-64. PubMed ID: 28910222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.
    Liao JM; Fischer MA
    Am J Public Health; 2017 Jun; 107(6):893-899. PubMed ID: 28426313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
    Girardin F; Goossens N; Vernaz N; Negro F
    Rev Med Suisse; 2015 Sep; 11(484):1610-2, 1614-6. PubMed ID: 26502622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.
    Lo Re V; Gowda C; Urick PN; Halladay JT; Binkley A; Carbonari DM; Battista K; Peleckis C; Gilmore J; Roy JA; Doshi JA; Reese PP; Reddy KR; Kostman JR
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1035-43. PubMed ID: 27062903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
    Canary LA; Klevens RM; Holmberg SD
    Ann Intern Med; 2015 Aug; 163(3):226-8. PubMed ID: 26121095
    [No Abstract]   [Full Text] [Related]  

  • 7. Accessing the cure: helping patients with hepatitis C overcome barriers to care.
    Rodriguez C; Reynolds A
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s108-12. PubMed ID: 27270155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
    Ooka K; Connolly JJ; Lim JK
    Am J Gastroenterol; 2017 Jun; 112(6):828-832. PubMed ID: 28374816
    [No Abstract]   [Full Text] [Related]  

  • 10. The changing face of hepatitis C in the new era of direct-acting antivirals.
    Soriano V; Labarga P; Fernández-Montero JV; Benito JM; Poveda E; Rallon N; Sánchez C; Vispo E; Barreiro P
    Antiviral Res; 2013 Jan; 97(1):36-40. PubMed ID: 23147192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. It's time to end insurance restrictions on life-saving hepatitis C treatments.
    Clary R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public funding for transformative drugs: the case of sofosbuvir.
    Barenie RE; Avorn J; Tessema FA; Kesselheim AS
    Drug Discov Today; 2021 Jan; 26(1):273-281. PubMed ID: 33011345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Federal AIDS policy issues today.
    James JS
    AIDS Treat News; 1997 Aug; (No 276):2-8. PubMed ID: 11364520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy for hepatitis C genotype 3: moving forward.
    Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
    J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
    Younossi Z; Henry L
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S186-96. PubMed ID: 25458773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized US Efforts to Eliminate Hepatitis C.
    Gaudino A; Gay B; Garmon C; Selick M; Vreeland R; Burk K; Huriaux E; Facente SN; Luetkemeyer A; Waters P; Graham CS
    Infect Dis Clin North Am; 2018 Jun; 32(2):293-311. PubMed ID: 29778257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationing hepatitis C treatment in the context of austerity policies in France and Cameroon: A transnational perspective on the pharmaceuticalization of healthcare systems.
    Chabrol F; David PM; Krikorian G
    Soc Sci Med; 2017 Aug; 187():243-250. PubMed ID: 28392011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.